Evotec SE announced that the Company has entered into a strategic collaboration with Ildong Pharmaceutical Co., Ltd., to accelerate the development of several of Ildong's proprietary projects through access to Evotec's INDiGO platform. Under the terms of the agreement, Evotec's experts in Integrated Development Solutions will accelerate the development of Ildong's projects with services from Evotec's comprehensive INDiGO platform, through to the filing with the regulatory authorities which enables clinical trials. Evotec and Ildong have agreed to jointly develop three to six projects, the first of which being IDG-16177, a glucose lowering drug candidate which is being evaluated as a treatment for type 2 diabetes.

The first regulatory filing is expected for the first quarter of 2021.